Acute lymphoblastic leukaemia trials in China

In China 168 Also abroad 563

168 trials · From ClinicalTrials.gov, checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 4Taking people
Asciminib Roll-over Study
Where
Beijing, Changchun, Chengdu, Chongqing, Guangzhou, Shanghai, Shenyang, Tianjin, Wuhan, Xian, Zhengzhou
Age
7 years to 100 years
People
347 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT04877522 · EU 2023-507557-16-00
No phaseNot yet taking people in China
Busulfan-Based Versus TBI-Based Conditioning for Adult ALL-CR2 Allo-HSCT
Where
Beijing
Age
14 years to 65 years
People
180
Run by
Peking University People's Hospital
See details and how to joinNCT07919470
Phase 1Taking people
In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies
Where
Kunming
Age
18 years and over
People
24
Run by
Chongqing Precision Biotech Co., Ltd
See details and how to joinNCT07239323
Phase 1/2Not yet taking people in China
CAR-T Immunotherapy Targeting CD19- ALL
Where
Shenzhen
Age
6 months to 75 years
People
100
Run by
Shenzhen Geno-Immune Medical Institute
See details and how to joinNCT04016129
Phase 1/2Not yet taking people in China
Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies
Where
Shenzhen
Age
6 months to 75 years
People
30
Run by
Shenzhen Geno-Immune Medical Institute
See details and how to joinNCT04033302
Phase 1Not yet taking people in China
Universal 4SCAR7U Targeting CD7-positive Malignancies
Where
Shenzhen
Age
6 months to 75 years
People
30
Run by
Shenzhen Geno-Immune Medical Institute
See details and how to joinNCT05995028
Phase 1Taking people
GN001 for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and B-Cell Acute Lymphoblastic Leukemia
Where
Kunming, Pu'er
Age
18 years to 75 years
People
42
Run by
Department of Hematology,Rheumatology and Immunology,Pu'er People's Hospital
See details and how to joinNCT07910708
Phase 1/2Taking people
A Clinical Study of MK-1045 (CN201) in People With Precursor B-cell Acute Lymphoblastic Leukemia (MK-1045-002)
Where
Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Shijiazhuang, Tianjin, Wuhan, Xuzhou, Zhengzhou
Age
2 years and over
People
203
Run by
MSD R&D (China) Co., Ltd.
See details and how to joinNCT05579132
Phase 1Taking people
Phase Ib Clinical Study of Keynatinib
Where
Beijing, Chengdu, Shanghai
Age
18 years and over
People
75
Run by
Medolution Ltd.
See details and how to joinNCT04807881
No phaseTaking people
Using Mobile Technology-assisted Outpatient Maintenance Therapy Pediatric ALL
Where
Tianjin
Age
Up to 16 years
People
100
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07278882
Phase 2Taking people
Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Patients
Where
Suzhou
Age
14 years to 75 years
People
27
Run by
The First Affiliated Hospital of Soochow University
See details and how to joinNCT07159620
Phase 1/2Taking people
Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia
Where
Guangzhou, Tianjin
Age
12 years and over
People
83 worldwide
Run by
AstraZeneca
See details and how to joinNCT07109219 · EU 2025-522372-93-00
Phase 1Taking people
Phase I Study of FXS0683 in the Treatment of Blood Tumors
Where
Tianjin
Age
18 years and over
People
228
Run by
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
See details and how to joinNCT07616089
Phase 1/2Taking people
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
Where
Changsha, Chengdu, Guangzhou, Hangzhou, Nanjing, Suzhou, Tianjin, Zhengzhou
Age
12 years and over
People
255 worldwide
Run by
AstraZeneca
See details and how to joinNCT06137118 · EU 2023-505840-20-00
Early phase 1Taking people
Study of GI001 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and B-Cell Acute Lymphoblastic Leukemia
Where
Yunnan
Age
18 years to 75 years
People
18
Run by
Hematology department of the 920th hospital
See details and how to joinNCT07862010
Phase 1Taking people
BEBT-908 in MEF2D-Rearranged Relapsed/Refractory or MRD-Positive B-Cell Precursor Acute Lymphoblastic Leukemia
Where
Suzhou
Age
14 years to 75 years
People
15
Run by
The First Affiliated Hospital of Soochow University
See details and how to joinNCT07854652
Phase 1Taking people
Dual-Targeted Umbilical Cord Blood CAR-T Cells Against CD19 and CD22 for the Treatment of Relapsed or Refractory Acute B-Cell Lymphoblastic Leukemia
Where
Shanghai
Age
18 years to 75 years
People
18
Run by
Ruijin Hospital
See details and how to joinNCT07838714
Phase 2Not yet taking people in China
Immunotargeted Therapy Plus Low-Dose Chemotherapy in Newly Diagnosed Adult Ph+ B-ALL
Where
Tianjin
Age
18 years and over
People
22
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07840976
Early phase 1Not yet taking people in China
SNC116 Therapy for Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
Where
Changchun
Age
18 years to 75 years
People
28
Run by
Shanghai Simnova Biotechnology Co.,Ltd.
See details and how to joinNCT07830238
Phase 2Taking people
A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents
Where
Beijing, Changsha, Chengdu, Chongqing, Hangzhou, Henan, Nanchang, Nanjing, Shenzhen, Suzhou, Tianjin, Wuhan
Age
3 years to 21 years
People
100
Run by
Chongqing Precision Biotech Co., Ltd
See details and how to joinNCT05334823
No phaseTaking people
Ph+ ALL in Chinese Children: Diagnosis, Treatment, and Survival
Where
Hangzhou
Age
1 month to 18 years
People
500
Run by
The Children's Hospital of Zhejiang University School of Medicine
See details and how to joinNCT07813208
No phaseTaking people
Blinatumomab Intensification for MRD-Negative Acute B-Cell Lymphoblastic Leukemia Before Allogeneic Hematopoietic Stem Cell Transplantation
Where
Hangzhou
Age
18 years to 65 years
People
114
Run by
First Affiliated Hospital of Zhejiang University
See details and how to joinNCT07003737
Phase 1Taking people
U69-CART-Cells For R/R T-ALL
Where
Suzhou
Age
15 years to 75 years
People
12
Run by
The First Affiliated Hospital of Soochow University
See details and how to joinNCT07350863
Phase 1Taking people
Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL
Where
Hefei, Jinan, Shanghai, Tianjin
Age
1 year to 18 years
People
19
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT05495035
Phase 1Enrolling by invitation
A Clinical Study of HY035 Cell Injection in the Treatment of CD7-positive Relapsed or Refractory Hematologic Malignancies
Where
Tianjin
Age
3 years to 70 years
People
13
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07784309